| 2025年中报 | 2024年年报 | |
|---|---|---|
| 营业收入(元) | ||
| 仿制药(元) | 36,628,844.20 | 55,520,356.11 |
| 医药技术服务(元) | 2,028,531.82 | 5,293,266.95 |
| 中间体及原料药(元) | 37,508,175.27 | 114,080,151.26 |
| 营业成本(元) | ||
| 仿制药(元) | 29,173,919.87 | 40,573,901.82 |
| 医药技术服务(元) | 653,704.36 | 4,432,162.16 |
| 中间体及原料药(元) | 36,369,442.18 | 82,247,367.68 |
| 毛利(元) | ||
| 仿制药(元) | 7,454,924.33 | 14,946,454.29 |
| 医药技术服务(元) | 1,374,827.46 | 861,104.79 |
| 中间体及原料药(元) | 1,138,733.09 | 31,832,783.58 |
| 毛利率(%) | ||
| 仿制药(%) | 20.35 | 26.92 |
| 医药技术服务(%) | 67.77 | 16.27 |
| 中间体及原料药(%) | 3.04 | 27.90 |
| 收入构成(%) | ||
| 仿制药(%) | 48.09 | 31.75 |
| 医药技术服务(%) | 2.66 | 3.03 |
| 中间体及原料药(%) | 49.25 | 65.23 |
| 毛利构成(%) | ||
| 仿制药(%) | 74.78 | 31.37 |
| 医药技术服务(%) | 13.79 | 1.81 |
| 中间体及原料药(%) | 11.42 | 66.82 |